U.S Department of Health and Human Services reports critical need for better prediction of severe sepsis.
The report entitled “National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011” found that the most expensive condition treated in hospitals is sepsis, accounting for $20,3 billion in annual costs to the U.S. healthcare system. In fact, sepsis represented 5.2% of the national costs for all hospitalizations in 2011, resulting in nearly 1.1 million discharges that year from U.S. hospitals.
Dr. James O’Brien, Jr., Medical Director of the NGO The Sepsis Alliance, comments the report at www.sepsisalliance.org:
“This is reaching the level of a national emergency. Early recognition of the symptoms of sepsis combined with prompt administration of fluids and antibiotics can make a huge difference not only in morbidity and mortality, but also in length of hospital stays and healthcare costs. Now more than ever, it is critical that we raise awareness of sepsis, which will reduce healthcare costs and, more importantly, save thousands of lives every year.”
The Sepsis Alliance comments that sepsis alone causes 258,000 deaths annually in the United States alone (one person every two minutes) and that there was a 32% increase in the total rate of sepsis hospitalizations counting from 2005 to 2010.
A tool for prevention of severe sepsis
HBP-analysis is a predictive diagnostic method patented and developed by Hansa Medical to help predict severe sepsis at Emergency Departments (ED). Fast and accurate prediction of severe sepsis dramatically increases the possibilities to save lives and avoid costly intensive care caused by sepsis. HBP-analysis can potentially facilitate earlier treatment and the prioritization of sepsis patients.
Pivotal clinical study with HBP-analysis
In a press release, dating November 5, 2013, Hansa Medical communicated results from a pivotal clinical study encompassing 763 ED-patients at Emergency Departments throughout Sweden and the U.S. The results show that HBP-analysis identified 80% of those ED-patients that later (within 72 hours) developed severe sepsis. Market estimation points to 3 million analyses per annum in Europe and U.S. alone.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com
Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in Phase I trial, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.
Tags:
